Head-to-head · WeighScore
REMEVi vs Rixa Health
The verdict
REMEVi takes it — 73.5/100 to 60.5/100.
REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | REMEVi | Rixa Health |
|---|---|---|
| WeighScore | 73.5/100 | 60.5/100 |
| Grade | C | C |
| Scorecard rank | #70 | #320 |
| Semaglutide | $219/mo | Not disclosed |
| Tirzepatide | $319/mo | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #70 · C
Strengths
- A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
- Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
- A daily oral semaglutide tablet is offered alongside the injection
- Available in all 50 states and DC, with no minimum commitment and no cancellation fee
Where it loses points
- The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
- No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #320 · C
Strengths
- Functional-medicine, root-cause clinical approach
- Compounded and oral semaglutide plus tirzepatide offered
- Board-certified DO and FNP providers with years of experience
- Medication bundled with visits into a single price
- No charge until after approval
Where it loses points
- No public monthly pricing; quoted only during consultation
- Relies on compounded GLP-1, which is not FDA-approved as a finished drug
- A handful of states still listed as coming soon
- Branded GLP-1 medications are not the primary offering
- Requires ongoing monthly follow-up commitment
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.